Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A Censuswide survey of 1,000 UK dieters, commissioned by nutrition brand PortionIQ, found that 29% of those using GLP-1 medications for two years or more lacked confidence in their knowledge of essential nutrients, compared with 12% of those in their first month. Only 57% of long-term users believed they were meeting their nutrient needs, against 81% of new users. With appetite suppression reducing total intake, nutrient density and protein adequacy become determinants of whether weight loss preserves or erodes lean mass and metabolic function.
A 12-week randomized, double-blind, vehicle-controlled trial of RLX-201, the active compound in Re-Q Longevity Face Serum, has been published in the Journal of Cosmetic Dermatology. Across 47 women aged 35 to 65 with moderate-to-severe photoaging, the company reports improvements in investigator-assessed firmness and cheek wrinkles of 21% from baseline at Week 12, with instrumented elastometry indicating improved viscoelastic properties from Week 8 onward and no adverse events in either arm.
Maze Therapeutics will present updated Phase 2 HORIZON data for MZE829, a dual-mechanism APOL1 inhibitor, in adults with APOL1-mediated kidney disease, alongside preclinical work on the SLC6A19 inhibitor MZE782. The company describes SLC6A19 inhibition as reducing nephrotoxin uptake and promoting a protective metabolic state in the proximal tubule, complementary to SGLT2 inhibition. Both programs target genetically and metabolically defined mechanisms of renal decline rather than downstream blood pressure or glycemic control.
Allergan Aesthetics presented two small open-label studies examining skin changes in people undergoing GLP-1-associated weight loss, reporting investigator-assessed improvements in dryness, tone, crepiness and texture with a topical regimen alone or combined with dermabrasion. The company also introduced the FACTS Principles, a voluntary checklist for evaluating exosome-based skincare covering formulation stability, analytical verification, clinical evidence, cellular origin and safety. Sample sizes were nine and eleven participants, and the most striking outcomes were participant perception measures rather than biological markers.
Junevity is applying its RESET discovery platform — which identifies transcription factors whose modulation shifts entire gene networks — to skin aging through a research collaboration and licensing agreement with Korean beauty group Amorepacific. The approach inverts conventional cosmetic development by starting with an aging mechanism rather than an ingredient, and raises the possibility of endpoints measured in gene expression and molecular age rather than wrinkle appearance. Skin, being visible, samplable and repeatedly measurable, offers an accessible testing ground for whether transcriptional reset translates to human tissue.
In a 12-week randomized trial of adults aged 45-65, creatine monohydrate at 10 grams daily increased lean tissue with or without a structured exercise and caloric-deficit program, and amplified fat-mass reduction and strength gains when combined with training. Leg-press maximum rose 34% with creatine plus exercise versus 18% with placebo plus exercise. Cognitive outcomes were inconsistent, and part of the lean-mass signal may reflect intracellular water retention rather than contractile tissue.
Single-cell DNA methylation mapping of human diseased kidneys and aging mouse kidneys identifies epithelial cell states that carry accelerated epigenetic age alongside altered methylation patterns and chromatin compartment structure. The same tubular epithelial populations also host spatially organized repair programs, placing molecular aging and regenerative capacity in the same cells. Chronic kidney injury therefore registers epigenetically as premature aging of the filtering epithelium rather than as generalized organ-wide decline.
Allergan Aesthetics has introduced AA Signature: SKIN360 in the US, a structured multimodal consultation protocol combining an injectable hydrator, a topical collagen-supporting formulation, and botulinum toxin for patients seeking smoother, more hydrated skin. The company cites internal figures on patient interest, retention, and treatment conversion tied to comprehensive assessment, while noting that the safety and efficacy of the featured products used in combination have not been studied. The launch reflects a broader shift in aesthetic medicine from single-product intervention toward protocolized, whole-face assessment.
Allergan Aesthetics reported results from two small single-center studies assessing topical skincare regimens, alone and paired with dermabrasion, in people undergoing medical weight loss including GLP-1 receptor agonist therapy. Investigators recorded statistically significant improvements in selected skin quality measures across the face, neck, upper inner arms and thighs, with some changes appearing by week two. The trials enrolled nine and eleven completers respectively, and the company states that larger studies are required.
A stem cell-derived secretome applied topically to ultraviolet-exposed mouse skin restored mitophagy, reduced senescent cell burden, preserved collagen, and improved barrier hydration and elasticity. Blocking mitophagy abolished the benefit, establishing damaged mitochondrial clearance as the causal mechanism rather than a correlate. The same pathway was confirmed in irradiated human keratinocytes.
A Lancet Healthy Longevity comment identifies medication safety as a neglected dimension of climate risk in older adults. Extreme heat, power failure, displacement, and pharmaceutical supply-chain disruption compromise the ability to access, store, and safely use medicines, while age-related physiology, multimorbidity, and polypharmacy magnify the consequences. The authors position medication safety as a core component of climate adaptation for ageing populations.
Core Biogenesis and Faravelli have developed a concept body formulation built around plant-produced biomimetic growth factors delivered in oleosome lipid capsules, extending actives previously reserved for facial skincare to the rest of the body. The product is not commercial; it functions as a demonstration that body care can be formulated around repair and renewal rather than surface hydration. The wider significance lies in skin being treated as a tissue with regenerative capacity rather than a cosmetic surface.